Trametinib (GSK1120212)

For research use only.

Catalog No.S2673 Synonyms: JTP-74057, Mekinist

994 publications

Trametinib (GSK1120212) Chemical Structure

CAS No. 871700-17-3

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Selleck's Trametinib (GSK1120212) has been cited by 994 publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.
Features More potent than PD0325901 or AZD6244.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
0.92 nM 1.8 nM
In vitro

GSK1120212 inhibits the phosphorylation of MBP regardless of the isotype of Raf and MEK, with IC50 ranging from 0.92 nM to 3.4 nM. GSK1120212 demonstrates no inhibition of the kinase activities of c-Raf, B-Raf, ERK1 and ERK2. In addition, GSK1120212 does not show drastic inhibitory activity against the other 98 kinases. GSK1120212 displays potent inhibitory activity against human colorectal cancer cell lines. HT-29 and COLO205 cells, which are known to have a constitutively active B-Raf mutant, are most sensitive to GSK1120212 with IC50 0.48 nM and 0.52 nM, respectively. The cell lines bearing a K-Ras mutation show a wide range of sensitivity to GSK1120212 with IC50 of 2.2-174 nM. In contrast, COLO320 DM cells, bearing the wild-type gene in both B-Raf and K-Ras, are found to be resistant to GSK1120212 even at 10 μM. GSK1120212 treatment for 24 hours induces cell-cycle arrest at the G1 phase in all sensitive cell lines. Consistently, GSK1120212 treatment leads to upregulation of p15INK4b and/or p27KIP1 in most of the colorectal cancer cell lines. GSK1120212 inhibits constitutive ERK phosphorylation in all sensitive cell lines. GSK1120212 induces apoptosis both in HT-29 and COLO205 cells, but that COLO205 cells are more sensitive to GSK1120212 than HT-29 cells in terms of apoptosis induction. [1] GSK1120212 blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (PBMCs). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231, SW480 and SW1116 cells NXLUPGpzTnWwY4Tpc44h[XO|YYm= M2\lU|ExOOLCiX7N NGfXNIUzPCCq M4G1PJRz[W2ndHnubYIh[2:3bHSg[IVkemWjc3WgXWFRKGyndnXsd{BidmRiaX7obYJqfCCOTVKtbY5lfWOnZDDZRXAhfXC{ZXf1cIF1cW:wIHnuJG1FSS2PQj2yN|EtKFOZMUGxOkBidmRiU2e0PFAh[2WubIO= M1voRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOEOzOlY2Lz5|MEizN|Y3PTxxYU6=
RG7388-resistant U87MG cells NUX0OW9bTnWwY4Tpc44h[XO|YYm= NHG3cYoyOCCwTR?= MYqyOEBp M4LVZWROW09? Ml\yWJJidWW2aX7pZkB1emWjdH3lcpQhemWmdXPl[EB1cGViaX72ZZNqfmVicHjlco91gXCnIH;mJHJIPzN6ODDy[ZNqe3SjboSgZ4VtdHNw MoTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{N{S5PFQoRjNyMke0PVg1RC:jPh?=
BJAB cells NXWwT4puTnWwY4Tpc44h[XO|YYm= M2nkcFAvODIQvF2= NHj0RmszPCCq MYWwMlAyKM7:TTD0doFu\XSrbnniJIVn\mWldHn2[Yx6KHO3cIDy[ZN{\WRidHjlJGVTUyCqeYDldoFkfGm4YYTpc44hcW5iQlrBRkBk\WyuczDjZZV{\WRiYomgeIhmKGOxbXLpcoVlKHS{ZXH0cYVvfCCxZjDCT20yOjBiYX7kJGRidnW|ZYL0bYIv MoLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7NEe1O|YoRjNyOUS3OVc3RC:jPh?=
Human PDAC cell lines (MIA-PACA, PANC-1, CFPAC-1, PL45, CAPAN-2 and HPAF-II) MYHGeY5kfGmxbjDhd5NigQ>? MXqxNEBvVSCxcjCxNFAhdk1? NGfESGY{NWSjeYOgc5IhPi2mYYnz NVW3WXkyXGinIHPvcoNmdnS{YYTpc44hd2ZiMUCgcm0hfHKjbXX0bY5q[iClb37zbZN1\W62bImgdJJw\HWlZXSgd4lodmmoaXPhcpQh\GmoZnXy[Y5k\XNiYnX0e4VmdiCpZX\peIlvcWJiYX7kJJRz[W2ndHnubYIh[WyxbnWgZ49ueGG{ZXSgeI8h[2:vYnnuZZRqd25iZ3XmbZRqdmmkIHHu[EB1emGvZYTpcoljKGmwIHHscEBnd3W{IIPlcpNqfGm4ZTDj[YxtKGyrbnXzJEhETlCDQz2xMEBxdDR3LDDDRXBCVi1{IHHu[EBJWEGILVnJLU4hVm9iYXTkbZRqfmViZX\m[YN1KHejczDvZpNmen[nZDDpckB1cGViZ3XmbZRqdmmkIHnud4Vve2m2aY\lJI9zKGW6Y3n0ZZRwenliY3XscEBtcW6nczCoUWlCNVCjY3GgZY5lKFCDTlOtNUk> NFn6Z3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEmyNVM2OSd-M{C5NlE{PTF:L3G+
Transitional cell carcinoma (TCC) cell lines NEXnV49HfW6ldHnvckBie3OjeR?= NUj6UW5UOjVibl2= M4\aW|YuOjRiaB?= NFLhN4dE[W6rbnWgWGNEKGOnbHygcIlv\XNiYYLlJJNmdnOrdHn2[UB1dyCPRVugbY5pcWKrdHnvci=> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB2OEW0PEc,OzFyNEi1OFg9N2F-
COLO205 NEHPNHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3XmR|czKGh? MYPJR|UxKD1iMD6wNFEh|ryP MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
HT-29 NYnjS3drT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHyRoNRPzJiaB?= MkHOTWM2OCB;IECuNFAyKM7:TR?= M1:3TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
COLO205 MorZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXe3NkBp NFzTWGJKSzVyIE2gNE4xODFizszN MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
MV522 MmHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF;MSnY4OiCq Ml:1TWM2OCB;IECuNFAyKM7:TR?= NX;JZXBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
HT-29 MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfMUFc4OiCq NV7UR5JuUUN3MDC9JFAvODB{IN88US=> MnHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
MV522 Mlr6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLaO|IhcA>? NEDmbnJKSzVyIE2gNE4xODJizszN NYj1eZdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
NCI-H727 M4TzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\QO|IhcA>? MmHtTWM2OCB;IECuNFAzKM7:TR?= NULafJpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
NCI-H727 NXjaWXhTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVu3NkBp NWjtc|ZmUUN3MDC9JFAvODB{IN88US=> M{\hS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
SW1417 M2DSR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXXO|IhcA>? NV;ndG1jUUN3MDC9JFAvODB|IN88US=> MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
SW1417 M3\jb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWrCdoZUPzJiaB?= MmjXTWM2OCB;IECuNFA{KM7:TR?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
Calu6 MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\CVFczKGh? NELwcW9KSzVyIE2gNE4xODNizszN MkjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
LS1034 MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NULUXWhbPzJiaB?= MlfQTWM2OCB;IECuNFA1KM7:TR?= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
SW1463 M1P4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfFN|E4OiCq M1X5UWlEPTBiPTCwMlAxPCEQvF2= NHm4eGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
SW1463 NHf6[IlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUO0W2VnPzJiaB?= NYDLdYlbUUN3MDC9JFAvODB2IN88US=> M4TRb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
Calu6 MmL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\meFczKGh? MkLlTWM2OCB;IECuNFA1KM7:TR?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
LS1034 M4PsbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mlu0O|IhcA>? MWPJR|UxKD1iMD6wNFUh|ryP M1X2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
RKO Mke3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfwXlA4OiCq MnLPTWM2OCB;IECuNFA2KM7:TR?= M1XzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
NCI-H508 NYLqfmRvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVy3NkBp NHuw[2FKSzVyIE2gNE4xODhizszN MlvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
KM12 NWOzcWc5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnk[VZmPzJiaB?= MYrJR|UxKD1iMD6wNUDPxE1? NEnvNlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
A427 M2HFWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkfxO|IhcA>? NXLye2Y5UUN3MDC9JFAvODFizszN M2HNZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
NCI-H1155 M4rCZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDaNFM4OiCq M4DVcGlEPTBiPTCwMlAyKM7:TR?= NUi1WGpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
HCT8 NYX3OJhiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml3JO|IhcA>? NGW1dFVKSzVyIE2gNE4xOTRizszN MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
MDA-MB-175-VII NXHVeZdDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk\sO|IhcA>? MVnJR|UxKD1iMD6wNVYh|ryP NWnCXGZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
A549 NVXGPW1qT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHtN3UyPzJiaB?= Mlq4TWM2OCB;IECuNFE3KM7:TR?= NHrrSGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
RKO NU\iOpYxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLpO|IhcA>? NWniT5FYUUN3MDC9JFAvODF6IN88US=> NHO4cHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H23 MoLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX23NkBp M3nyRWlEPTBiPTCwMlAzKM7:TR?= MlHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
A427 NGjRZVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHQO|IhcA>? MnnUTWM2OCB;IECuNFIzKM7:TR?= NHrwbY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
KM12 NYWxVVVMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWP3d|B7PzJiaB?= NW[zOZBpUUN3MDC9JFAvODJ|IN88US=> NXi5TI9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
NCI-H508 NVnud5Y2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4fHZVczKGh? M{LF[mlEPTBiPTCwMlAzOyEQvF2= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNVA{QDd3Lze+R4hGVUKOPD;hQi=>
MDA-MB-231 M33nemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUK5Rm5OOyCmYYnz Mm\qS2k2OCB;IECuNFI2KM7:TR?= M3;TbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
SW837 M4LLRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzlO|IhcA>? Moe2TWM2OCB;IECuNFI2KM7:TR?= NXfkcFlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
SW480 M2\MeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjPW4puPzJiaB?= M2fPN2lEPTBiPTCwMlAzPiEQvF2= Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
NCI-H1355 MmPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mln5O|IhcA>? Mn\HTWM2OCB;IECuNFI4KM7:TR?= NEn6c449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H23 M125UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkXPO|IhcA>? NWLHemRsUUN3MDC9JFAvODJ7IN88US=> NH7EeFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
EFM19 MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX:3NkBp M2DWNGlEPTBiPTCwMlA{KM7:TR?= MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
T84 NEDOWmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mnf4O|IhcA>? NFu0VpNKSzVyIE2gNE4xOyEQvF2= MmLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
A549 M1j4T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nTRVczKGh? MXHJR|UxKD1iMD6wN|Qh|ryP NIq5bnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H1792 NVLGRXRMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWq3NkBp NVXPcnlPUUN3MDC9JFAvODN3IN88US=> M1O0flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
SW480 MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXq3NkBp NUHlW3Q{UUN3MDC9JFAvODN5IN88US=> NWT6[oFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
COR-L23 MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXK3NkBp NULhcW9yUUN3MDC9JFAvODN5IN88US=> NYPIOW1XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
SW1573 NI\zNpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLleXU4OiCq NHfkOWdKSzVyIE2gNE4xOzhizszN NVvPO25FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
Calu3 NWjhZWR4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF\kSY44OiCq MVvJR|UxKD1iMD6wN|kh|ryP M3zaflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
HCC827 NHf1fIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonWO|IhcA>? NWf6TnNxUUN3MDC9JFAvODRizszN M3zRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
HOP62 MnWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;qbI4zPzJiaB?= MkLUTWM2OCB;IECuNFUh|ryP NELVUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H1355 M2DrXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHe2VYM4OiCq NX3SSJN6UUN3MDC9JFAvODV{IN88US=> NEHic5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
NCI-H1792 NELMVIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYmxZ4VwPzJiaB?= NF3wXGhKSzVyIE2gNE4xPTNizszN MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
HCT8 MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1XtUVczKGh? MXXJR|UxKD1iMD6wOVUh|ryP NYH6THQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
T84 Mmn1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mk\YO|IhcA>? NEXkeHFKSzVyIE2gNE4xPjFizszN NHHOWHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
SW900 Mon3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml6xO|IhcA>? MnvBTWM2OCB;IECuNFczKM7:TR?= M{nOSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
SW837 NIm5[G1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYS3NkBp Ml3qTWM2OCB;IECuNFc1KM7:TR?= M1;wb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIyODN6N{WvK|5EcEWPQly8M4E,
DLD1 NYS4Spc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWPOOopTPzJiaB?= MlrBTWM2OCB;IECuNFk{KM7:TR?= NYL4TZN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
MDA-MB-175-VII NYHDbG9ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXRVJA4OiCq M3\mWmlEPTBiPTCwMlA6PiEQvF2= NUjrcXdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjFyM{i3OU8oRkOqRV3CUFww[T5?
SW900 M1rqRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjMWJVNPzJiaB?= NFmwem5KSzVyIE2gNE4yOjdizszN NFLq[2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
Calu3 Mn[xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHn3dlI4OiCq M{C0OGlEPTBiPTCwMlE2QCEQvF2= NHjCTHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOTB|OEe1M{c,S2iHTVLMQE9iRg>?
COR-L23 NHKw[JFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGn3U5Q4OiCq MXHJR|UxKD1iMD6zNlkh|ryP MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>
DLD1 NIGwVnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrKeZZ2PzJiaB?= M{O3U2lEPTBiPTCwMlY{OiEQvF2= MojHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlExOzh5NT:nQmNpTU2ETEyvZV4>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ERRα / IDH3 / c-Myc / Cyclin D1; 

PubMed: 30185207     


WB for ERRα, IDH3A, c-Myc and Cyclin D1 in the HCT116 and SW480 cells treated with the indicated concentrations of trametinib (0–100 nM) or DMSO for 48 h. 

pERK /ERK / pS6 / S6 ; 

PubMed: 29133622     


BRAF/NRAS-WT cell lines were treated with vehicle, ceritinib, trametinib or ceritinib-trametinib for 24h before extraction of protein and Western blot for pERK or pS6. Numbers above pS6 indicate the densitometry measurements expressed as a proportion of total S6. 

β-catenin; 

PubMed: 28422736     


The antibodies against phospho-ERK (p-ERK), total ERK (t-ERK) and β-catenin were used to determine the effect of trametinib on the levels of p-ERK and β-catenin in the indicated cells. GAPDH was used as a loading control.

30185207 29133622 28422736
Growth inhibition assay
Cell proliferation; 

PubMed: 30185207     


Cell proliferation was measured using the Cell Counting Kit-8 (CCK-8) assay in the HCT116 and SW480 cells treated with trametinib at 25 nm, 50 nM and 100 nM for 3 d.

MTT assay; 

PubMed: 26832408     


Percent viability of A549 cells determined by MTT assay plotted on a logarithmic molar dose curve scale. Shown are trametinib and fluvastatin single drug dose curves and fluvastatin dose curve with fixed trametinib dosing.

30185207 26832408
Immunofluorescence
phospho-PR(S345); 

PubMed: 29237804     


IF of the nuclear phospho-PR (S345) in ISHIKAWA cells treated with 10 μM onapristone, 100nM trametinib, or a combination for 24 hours.

β-catenin; 

PubMed: 28422736     


Immunofluorescence assay was used to investigate the effect of trametinib on subcellular localization of β-catenin in NOZ and GBC-SD cells. Red color represents nuclear and cytoplasmic staining of β-catenin, and blue color represents Hoeschst 33342 staining for nuclei. Scale bars, 200 μm.

29237804 28422736
In vivo Oral administration of GSK1120212 at 0.3 mg/kg or 1 mg/kg once daily for 14 days is effective in inhibiting the HT-29 xenograft growth, and 1 mg/kg of GSK1120212 almost completely blocks the tumor increase. The phosphorylation of ERK1/2 is completely inhibited in the established tumor tissues by single oral dose of 1 mg/kg GSK1120212, and both p15INK4b and p27KIP1 protein levels are upregulated after 14 days of treatment with GSK1120212. In the COLO205 xenograft model, tumor regression is observed even at a dose of 0.3 mg/kg. At a dose of 1 mg/kg, a complete regression is obtained in 4 out of 6 mice in which the tumor degenerates to the point that tumor volume is not measurable. [1] Administration of GSK1120212 at 0.1 mg/kg almost completely suppresses adjuvant-induced arthritis (AIA) and type II collagen-induced arthritis (CIA) in Lewis rats or DBA1/J mice, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Raf-MEK-ERK cascade kinase assay:

Non-phosphorylated myelin basic protein (MBP) is coated onto an ELISA plate, and the active form of B-Raf/c-Raf is mixed with unphosphorylated MEK1/MEK2 and ERERK2 in 10 μM ATP and 12.5 mM MgCl2 containing MOPS buffer in the presence of various concentrations of GSK1120212. The phosphorylation of MBP is detected by the anti-phospho-MBP antibody.
Cell Research:[1]
- Collapse
  • Cell lines: HT-29, HCT-15, HCT116, COLO205, LS-174T, SW480, SW620, T84, LoVo and COLO320
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 3 or 4 days
  • Method: Exponentially growing cells are precultured in 96-well tissue culture plates for 24 hours and then exposed to GSK1120212. Cell growth is determined by an in vitro toxicology assay kit, sulforhodamine B based. For apoptosis assay, both floating and adherent cells are collected and fixed with 70% ethanol. After washing with PBS, the cells are suspended in 100 μg/mL RNase and 25 μg/mL propidium iodide (PI) and incubated at 37 °C for 30 minutes in the dark. The DNA content of each single cell is determined using the flow cytometer Cytomics FC500 or Guava EasyCyte plus.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female BALB/c-nu/nu mice inoculated subcutaneously with HT-29 or COLO205 cells
  • Dosages: ~1 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 22 mg/mL warmed (35.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+corn oil
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 615.39
Formula

C26H23FIN5O4

CAS No. 871700-17-3
Storage powder
in solvent
Synonyms JTP-74057, Mekinist
Smiles CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04961619 Not yet recruiting Drug: dabrafenib|Drug: trametinib Melanoma Novartis Pharmaceuticals|Novartis October 20 2021 --
NCT04547946 Not yet recruiting Drug: dabrafenib + trametinib Malignant Melanoma Novartis Pharmaceuticals|Novartis September 30 2021 --
NCT04566133 Recruiting Drug: Trametinib|Drug: Hydroxychloroquine Bile Duct Cancer|Biliary Cancer|Biliary Tract Neoplasms|Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 7 2021 Phase 2
NCT04454476 Not yet recruiting Drug: Trametinib treatment|Procedure: Endoscopy Gastric Cancer|Metaplasia|Stage I Gastric Cancer|Initial-onset Gastric Cancer Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) September 2021 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you help us with the best way to prepare Trametinib for in vivo i.p. injections?

  • Answer:

    S2673 can be dissovled in 4% DMSO/corn oil at 3 mg/ml clearly.

  • Question 2:

    How to solve the problem that this product didn't dissolve up to 10mM in DMSO at room temperature?

  • Answer:

    The solution can be heated up to 50 degree to help dissolve. Besides, sonication (with a probe sonicator) also helped greatly.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy Trametinib (GSK1120212) | Trametinib (GSK1120212) supplier | purchase Trametinib (GSK1120212) | Trametinib (GSK1120212) cost | Trametinib (GSK1120212) manufacturer | order Trametinib (GSK1120212) | Trametinib (GSK1120212) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID